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Abstract
Aim To examine the extent to which discriminatory testing using antibodies and Type 1 diabetes genetic risk score,
validated in European populations, is applicable in a non-European population.
Methods We recruited 127 unrelated children with diabetes diagnosed between 9 months and 5 years from two centres
in Iran. All children underwent targeted next-generation sequencing of 35 monogenic diabetes genes. We measured three
islet autoantibodies (islet antigen 2, glutamic acid decarboxylase and zinc transporter 8) and generated a Type 1 diabetes
genetic risk score in all children.
Results We identified six children with monogenic diabetes, including four novel mutations: homozygous mutations in
WFS1 (n=3), SLC19A2 and SLC29A3, and a heterozygous mutation in GCK. All clinical features were similar in
children with monogenic diabetes (n=6) and in the rest of the cohort (n=121). The Type 1 diabetes genetic risk score
discriminated children with monogenic from Type 1 diabetes [area under the receiver-operating characteristic curve 0.90
(95% CI 0.83–0.97)]. All children with monogenic diabetes were autoantibody-negative. In children with no mutation,
59 were positive to glutamic acid decarboxylase, 39 to islet antigen 2 and 31 to zinc transporter 8. Measuring zinc
transporter 8 increased the number of autoantibody-positive individuals by eight.
Conclusions The present study provides the first evidence that Type 1 diabetes genetic risk score can be used to distinguish
monogenic from Type 1 diabetes in an Iranian population with a large number of consanguineous unions. This test can be
used to identify children with a higher probability of having monogenic diabetes who could then undergo genetic testing.
Identification of these individuals would reduce the cost of treatment and improve the management of their clinical course.
Diabet. Med. 36, 1694–1702 (2019)
Introduction
The accurate diagnosis of diabetes subtypes is challenging,
especially in young children in whom monogenic diabetes is
often misdiagnosed as Type 1 diabetes [1–5]. The correct
diagnosis is crucial because the best management for each
subtype is different. People with Type 1 diabetes require
lifelong insulin treatment, while those with particular
monogenic diabetes subtypes such as GCK, HNF1A and
HNF4A maturity-onset diabetes of young (MODY) can be
treated without insulin [6,7]. Misdiagnosis of monogenic
diabetes as Type 1 diabetes can result in unnecessary insulin
treatment, causing suboptimal glucose control, higher man-
agement costs and avoidable side effects. Furthermore,
correct diagnosis improves clinical care by guiding anticipa-
tion of the development of related features and enabling
testing for at-risk family members [7–9].
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The likelihood of diagnosing monogenic diabetes in
paediatric cohorts can be improved by the use of biomarkers
for Type 1 diabetes. Combined islet autoantibody testing
against glutamic acid decarboxylase (GAD), islet antigen 2
(IA2) and zinc transporter 8 (ZnT8) can discriminate
between autoimmune Type 1 diabetes and monogenic
diabetes with a high degree of sensitivity and specificity
[10–13]. The Type 1 diabetes genetic risk score is a more
recent discriminative tool for Type 1 diabetes that is
calculated based on the number of risk alleles (weighted by
their effect on risk of Type 1 diabetes) each individual carries
[14,15]. Studies of white European populations with low
rates of consanguinity (1–4% of marriages [16]) have shown
that the Type 1 diabetes genetic risk score has a high ability
to discriminate between Type 1 diabetes and monogenic
diabetes, enabling the exclusion of people with probable
Type 1 diabetes from inappropriate genetic testing [12,17].
Discriminatory testing using antibodies and Type 1 diabetes
genetic risk score has been developed and validated in
European populations only, and the extent to which these
tests improve the accurate diagnosis of diabetes subtypes in
other populations is not known.
By testing autoantibodies, using a Type 1 diabetes genetic
risk score and sequencing of all known monogenic diabetes
genes in an unselected paediatric diabetes cohort, we aimed
to determine whether triple antibody testing (GAD, IA2 and
ZnT8) and the Type 1 diabetes genetic risk score could
distinguish monogenic diabetes from Type 1 diabetes in the
Iranian population where >30% of marriages are consan-
guineous [18–20]. We also report for the first time the
frequency of islet autoantibodies and prevalence of mono-
genic subtypes in Iranian children with diabetes using a
genetic test for all subtypes of monogenic diabetes.
Participants and methods
Study participants
We recruited 127 unrelated children with diabetes diagnosed
between the ages of 9 months and 5 years from two centres in
Iran [Imam Reza Hospital, Mashhad, Iran and the Division
of Endocrinology and Metabolism in the Department of
Paediatrics at the Children’s Medical Centre in Tehran, Iran
(Table 1)]. Clinical information was supplied by the referring
clinicians. Informed consent was obtained from parents on
behalf of their children. Peripheral blood samples were
collected from affected children and their parents at the time
of referral and used to measure islet autoantibodies and
perform genetic testing.
Cohort characteristics
Our cohort of 127 children included 64 girls and 63 boys; of
these 41 children came from consanguineous families
(32.2%; Table 1). The median [interquartile range (IQR)]
age at diagnosis was 3 (2–4) years. A total of 125 children
(98%) were on insulin treatment at the time of study
recruitment. Two children (2%) were non-insulin-treated,
including one child who was receiving oral agents. The
median (IQR) last HbA1c value was 65.0 (56.3–79.2) mmol/
mol [8.1 (7.3–9.4)%] for 98 children with data available.
Genetic testing
DNA was extracted, using standard methods, at the Exeter
Molecular Genetics Laboratory (Exeter, UK). All children
underwent targeted next-generation sequencing of 35 known
monogenic diabetes genes (Table S1) as previously described
[14,21]. All putative mutations were confirmed by Sanger
sequencing or digital droplet PCR (primers available on
request) in the probands and both parents.
Variants were classified according to the American College
of Medical Genetics and Genomics and the Association for
Molecular Pathology standards and guidelines for the inter-
pretation of sequence variants [22]. We checked the frequen-
cies of the identified variants in GnomAD [>120 000
individuals (http://gnomad.broadinstitute.org)] and in
human variant and mutation databases, such as ClinVar
and Human Gene Mutation Database, as well as in the
literature via PubMed and Google searches. The in silico
tools SIFT, PolyPhen-2 and Align GVGD were used to assess
the pathogenicity of missense variant effects, and the
prediction of variant effect on mRNA splicing was made
using SpliceSiteFinder-like, MaxEntScan, GeneSplice,
NNSPLICE and Human Splicing Finder. All in silico
programs were accessed through the ALAMUT Visual
software version 2.7.1 (Interactive Biosoftware, Rouen,
France). Conservation of amino acids and nucleotides across
What’s new?
• Studies in white European populations have recently
shown that a genetic risk score for Type 1 diabetes has a
high ability to discriminate between Type 1 diabetes
and monogenic diabetes.
• The diagnostic utility of this genetic risk score in non-
European populations is unknown.
• This study provides the first evidence that the Type 1
diabetes genetic risk score discriminates children with
monogenic diabetes from those with Type 1 diabetes in
the Iranian population with a large number of consan-
guineous unions.
• The Type 1 diabetes genetic risk score can be used to
improve the selection of non-European children for
monogenic diabetes testing, resulting in the correct
diagnosis, improving their clinical management and
providing families with recurrence risk information.
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multiple species was performed using the University of
California Santa Cruz genome browser (http://genome.uc
sc.edu).
Antibody testing
The GAD, IA2 and ZnT8 antibody testing was performed by
the Exeter Academic Department of Blood Sciences at the
Royal Devon and Exeter Hospital (Exeter, UK). We used
commercially available ELISA assays (RSR, Cardiff, UK) on
the Dynex DS2 ELISA Robot (Dynex Technologies, Wor-
thing, UK). Thresholds for positivity were based on the
97.5th centile of 1500 controls [10]: GAD ≥11U/ml, IA2
≥7.5U/ml and ZnT8 ≥65U/ml.
Type 1 diabetes genetic risk score
We genotyped by targeted next-generation sequencing the top
nine single nucleotide polymorphisms (SNPs) with the largest
effect size on Type 1 diabetes, as previously described [15],
including both HLA and non-HLA regions. The Type 1
diabetes genetic risk score was calculated per individual
according to the sum of the number of risk-increasing alleles
across SNPs.Eachallelewasweightedby its effect on the riskof
Type 1 diabetes [ln(odds ratio)], assuming that each risk allele
had a log-additive effect on Type 1 diabetes risk (Table S2).
Type 1 diabetes cases and controls of European descent
We used Type 1 diabetes case and control individuals from
the Wellcome Trust Case Control Consortium (WTCCC) as
previously described [15,23]. This cohort includes 1963
individuals with diabetes diagnosed before the age of 17
years and treated with insulin from diagnosis.
Homozygosity mapping
We defined children born to consanguineous parents as
those whose parents were known to be first or second
cousins (n=37), or where homozygosity mapping calculated
directly from next-generation sequencing off-target reads
using SavvyHomozygosity [24,25] showed >3% of their
genome covered by homozygous regions >3Mb [26]. This
threshold roughly reflects second cousins in levels of
relatedness.
Statistical analysis
We used chi-squared analysis to compare proportions (e.g.
number of antibody positives) and Wilcoxon’s rank-sum
test to compare continuous characteristics (e.g. age of
diagnosis) between children with and without monogenic
cause. A P value < 0.05 was taken to indicate statistical
significance. Continuous data are expressed as median and
IQR since they were not normally distributed. Logistic
regression and receiver-operating characteristic (ROC)
curve analysis were used to measure the discriminatory
power of the Type 1 diabetes genetic risk score. Statistical
analyses were performed in STATA 14 (StataCorp, College
Station, TX, USA).
Ethics approval
The study was approved by the institutional review board of
Tehran University of Medical Sciences and Mashhad Univer-
sity of Medical Sciences. All procedures performed in this
study were in accordance with the ethical standards of the
1964 Helsinki declaration and its later amendments or
comparable ethical standards.
Table 1 Clinical characteristics of the cohort
All Monogenic diabetes Type 1 diabetes P for difference
Number of children (boys, girls) 127 (63, 64) 6 (2, 4) 121 (61, 60) 0.70
Age at diagnosis, years (IQR) 3 (2–4) 3.2 (2–4.4) 3.3 (1.9–4.1) 0.84
Significant regions of homozygosity, n (%) 63 (49.6) 5 (83.3) 58 (47.9) 0.11
Last HbA1c, mmol/mol (IQR) 65.0 (56.3–79.2) 66.1 (57.4–103.3) 65.0 (56.3–79.2) 0.76
Last HbA1c, % (IQR) 8.1 (7.3–9.4) 8.2 (7.4–11.6) 8.1 (7.3–9.4) 0.76
GAD-positive, n (%) 59 (47.2) 0 (0) 59 (48.8) 0.03
IA2-positive, n (%) 39 (31.2) 0 (0) 39 (32.2) 0.18
ZnT8-positive, n (%) 31 (24.8) 0 (0) 31 (25.6) 0.34
Positive for at least one antibody, n (%) 84 (67.2) 0 (0) 84 (69.4) 0.001
Positive for two antibodies, n (%) 21 (16.8) 0 (0) 21 (17.4) 0.58
Positive for three antibodies, n (%) 12 (9.6) 0 (0) 12 (9.9) 1
Insulin treatment at diagnosis, n (%) 124 (97.6) 4 (66.7) 120 (99.2) 0.006
Insulin treatment at recruitment, n (%) 125 (98.4) 4 (66.7) 119 (98.4) 0.006
Syndromic features, n (%) 38 (30) 3 (50) 35 (28.9) 0.36
Duration of diabetes, days 589 (53–1689) 710 (37–1746) 589 (61–1684) 0.51
Parent affected with diabetes, n (%) 12 (9.4) 1 (16.7) 11 (9.1) 0.51
Type 1 diabetes genetic risk score (IQR) 10.8 (9.5–11.6) 8.4 (8–8.8) 10.8 (9.7–11.6) 0.005
GAD, glutamic acid decarboxylase; IA2, islet antigen 2; IQR, interquartile range; ZnT8, zinc transporter 8.
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Results
Targeted next-generation sequencing to identify monogenic
diabetes
Targeted next-generation sequencing enabled a genetic diag-
nosis of monogenic diabetes in six out of 127 children (4.7%;
Table 2). Five children had homozygous mutations in genes
causing recessive syndromic forms of monogenic diabetes. A
homozygous mutation in WFS1 was identified in three
children; mutations in this gene cause Wolfram syndrome, a
recessive disorder characterized by childhood-onset diabetes
mellitus, optic atrophy and deafness. One child had a novel
frameshift homozygous mutation (c.547del; p.Met183fs) and
had other features of Wolfram syndrome, including partial
hearing loss in the right ear. The other two children had
isolated diabetes and known pathogenic missense homozy-
gous mutations (c.1010C>T; p.Thr337Ile and c.2105G>A;
p.Gly702Asp); they had not developed any other features of
Wolfram syndrome by age 4 and 9 years, respectively.
One child had developmental delay, anaemia, cardiac
defects, low weight, hearing loss and low sight in the left eye.
These clinical features are consistent with a diagnosis of
thiamine-responsemegaloblasticanaemia(TRMA),arecessive
syndromecausedbymutations inSLC19A2 [27].Thediagnosis
of TRMA was confirmed by identifying a homozygous novel
SLC19A2 nonsense mutation (c.242dup; p.Tyr81*).
A pathogenic homozygous frameshift mutation in the
SLC29A3 (c.122del; p.Pro41fs) was identified in another
child with isolated diabetes. Mutations in this gene cause H
syndrome, characterized by cutaneous findings and multi-
system involvement [28], but the child in the present study
had no other clinical features of this syndrome at the age of
5.5 years.
The childwithanovel substitutionheterozygousmutation in
GCK (c.364-8T>G) had a phenotype consistent with glucok-
inase MODY [persistent fasting hyperglycaemia in the range
5.7–6.4 mmol/l, HbA1c 50.8 mmol/mol (6.8%) without treat-
ment and a small postprandial increase in blood glucose
evidencedbya2-horalglucosetolerancetestvalueof7.1mmol/l].
In silico splicing predictions provided evidence to support an
aberrant effect on splicing. The variant was also present in the
motherandmaternalaunt,whoweresimilarlyaffected.Thesame
GCK splicing variant was identified in another Iranian family
with clinical features of GCK MODY referred for diagnostic
MODY testing to Exeter Molecular Genetics Laboratory.
Further information from the family confirmed they came from
the same region inNorth East of Iran.
Use of Type 1 diabetes genetic risk score to discriminate
children with monogenic diabetes from Type 1 diabetes
No pathogenic variants were identified in any of the known
monogenic diabetes genes in 121/127 children. Having
excluded all known monogenic causes, the most likely
diabetes aetiology in this age group is Type 1 diabetes, and
this diagnosis was assigned to the 121 children without a
monogenic diagnosis. We then assessed the utility of the
Type 1 diabetes genetic risk score in indicating the aetiology
of diabetes. Children with monogenic diabetes (n=6) had a
significantly lower median (IQR) Type 1 diabetes genetic risk
score than the rest of the cohort [8.4 (8–8.8) vs 10.8 (9.7–
11.6)], equivalent to seventh vs 53rd centile in the WTCCC
Type 1 diabetes cohort; P = 0.005 (Fig. 1)]. Children with
mutations (n=6) had a similar median (IQR) Type 1 diabetes
genetic risk score to that of the WTCCC control cohort [8.4
(8–8.8) vs 8.1 (6.9–9.4)], while the rest of the cohort (n=121)
had a median (IQR) genetic risk score similar to that of the
WTCCC Type 1 diabetes cohort [10.8 (9.7–11.6) vs 10.7
(9.7–11.7); Fig. 1].
The ROC curve analysis showed that the Type 1 diabetes
genetic risk score was highly discriminatory between mono-
genic and Type 1 diabetes in our cohort [area under the ROC
curve 0.90 (95% CI 0.83–0.97)], which was similar to the
ability of same genetic risk score in the WTCCC Type 1
diabetes cohort to discriminate Type 1 diabetes from controls
[area under the ROC curve 0.87 (95% CI 0.86–0.88);
Fig. 2]. A Type 1 diabetes genetic risk score threshold of <9.2
(equivalent to 15th centile for Type 1 diabetes) identified all
cases of monogenic diabetes (~100% sensitivity and 82%
specificity). Using this threshold, we calculated that five
children would need to undergo genetic testing to find one
case of monogenic diabetes.
Measuring all three islet antibodies in the diagnosis of Type 1
diabetes
The analysis of islet autoantibodies was successful for 125/
127 children. All children with monogenic diabetes were islet
autoantibody-negative. In 121 children with no mutation, 84
(71%) were positive for at least one antibody and 37 (29%)
were negative for all three autoantibodies. A total of 59 were
positive for GAD, 39 were positive for IA2 and 31 were
positive for ZnT8. Twenty-one children were positive for any
two antibodies and 12 were positive for all three antibodies
(Table 1). Children positive for only one antibody included
31 for GAD only, 12 for IA2 only, and eight for ZnT8 only
(Fig. 3). Measuring ZnT8 increased the number of auto-
antibody-positive individuals from 76 to 84, indicating the
importance of testing for all three autoantibodies.
Clinical features in children with monogenic diabetes and
those with Type 1 diabetes
Age of diagnosis (P = 0.84), consanguinity (P = 0.11), last
HbA1c value (P = 0.76), syndromic features (P = 0.36),
gender (P = 0.70), duration of diabetes (P = 0.51) and
proportion of children with a parent who had diabetes (P =
0.51) were similar in children with monogenic diabetes and
the remainder of the cohort (Table 1). Children with Type 1
ª 2019 The Authors.
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diabetes were significantly more likely to be insulin-treated at
the time of diabetes diagnosis and at the time of recruitment
into the study.
Discussion
We have provided the first evidence to suggest that the Type
1 diabetes genetic risk score may help to distinguish
monogenic diabetes from Type 1 diabetes in an Iranian
population with a large number of consanguineous unions.
Six children with monogenic diabetes had a lower Type 1
diabetes genetic risk score than those with probable Type 1
diabetes. The age at diagnosis, consanguinity, presence of
other symptoms and parental diabetes status were similar in
the two groups and did not aid discrimination, highlighting
the need for a non-clinical marker for selecting children for
monogenic diabetes testing.
The present study provides evidence that the Type 1
diabetes genetic risk score could be used in clinical practice in
non-European ethnic groups, such as Iranians. Iran is a
Middle Eastern country with a high prevalence of diabetes
(11.1%) [29], obesity [30] and consanguinity (37.4% of
marriages [31]). The features of diabetes in Iran means
people with diabetes are likely to be misclassified because
those with Type 1 diabetes may be overweight, and family
history may not distinguish monogenic forms. High rates of
consanguinity mean that many undiscovered monogenic
recessive forms of diabetes may exist in the population. All
these factors suggest standard clinical criteria used in Europe
may not translate well to a Middle Eastern setting.
We propose that GAD, IA2 and ZnT8 autoantibody
testing, in combination with the Type 1 diabetes genetic risk
score, could be used to prioritize individuals for genetic
testing. There were 13 children in our cohort who were islet
autoantibody-negative and had a Type 1 diabetes genetic risk
score below that of the 15th centile of European people with
WTCCC Type 1
diabetes
Type 1
diabetes
FIGURE 1 Dot plots of Type 1 diabetes genetic risk score stratified by
disease in cases and controls from the Wellcome Trust Case Control
Consortium (WTCCC). Type 1 diabetes genetic risk score is higher in
children with Type 1 diabetes than in those with confirmed monogenic
diabetes. The red central line represents the median and the green upper
and lower lines represent the interquartile range.
FIGURE 2 The ability of a nine-single nucleotide polymorphism (SNP)
Type 1 diabetes genetic risk score to discriminate between Type 1 and
other types of diabetes in our cohort (a) and in the Wellcome Trust
Case Control Consortium study (b). ROC, receiver-operating
characteristic.
FIGURE 3 Graph illustrating that measurement of all three islet
antibodies can improve the diagnosis of Type 1 diabetes. GAD,
glutamic acid decarboxylase; IA2, islet antigen 2; ZnT8, zinc
transporter 8.
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Type 1 diabetes. Among these children, we confirmed
monogenic diabetes in six; therefore, in three islet anti-
body-negative children with a genetic risk score <15th
centile, we need to test two cases to obtain one monogenic
diabetes diagnosis (~50% identification rate). Studies of
larger numbers of children in this age range would enable us
to use islet autoantibodies and Type 1 diabetes genetic risk
score to provide a screening pathway for monogenic diabetes
in this population.
Although the number of individuals with monogenic
diabetes in the present cohort was low, to our knowledge,
this is the first report of using targeted next-generation
sequencing to diagnose monogenic diabetes in young Iranian
children described in the literature to date. A diagnosis of
monogenic diabetes was confirmed in six children, with five
(83%) having a recessive, syndromic subtype. Mutations in
WFS1 (associated with Wolfram syndrome) accounted for
50% of the monogenic diabetes cases. This is significantly
higher than the 0.1% estimate of Wolfram syndrome
prevalence in a European paediatric population [32]. Wol-
fram syndrome is recessively inherited and the median age of
diabetes diagnosis in that population was 6 years (range 3
weeks to 17 years) [33]. The high prevalence was therefore
not unexpected given the consanguineous nature of the
present cohort and the age range of diabetes diagnosis.
It is likely that in a similar age group in a non-
consanguineous European population, the overall diagnostic
yield from monogenic diabetes testing would be lower owing
to the absence of rare recessive subtypes. In the UK
population, HNF1A MODY is the most common cause of
monogenic diabetes outside of the neonatal period [34].
Because of the progressive nature of the b-cell defect, those
with HNF1A MODY are normoglycaemic at birth and early
childhood but develop diabetes as teenagers and early adults
[35]. Fewer than 1% of HNF1AMODY cases are diagnosed
under the age of 10 years [36]. GCK MODY is the second
most common subtype; people who have this subtype are
typically asymptomatic and are often diagnosed incidentally
when fasting blood glucose testing is undertaken for other
purposes (e.g. during pregnancy, illness or routine medical
screening) [37]; therefore, almost all monogenic diabetes in
the UK diagnosed between the ages of 1 to 5 years would be
GCK MODY and only very rarely attributable to recessive
syndromic subtypes.
The Type 1 diabetes genetic risk score could enable the
diagnosis of syndromic forms of monogenic diabetes when
clinical features are not present. Among three children with a
mutation in WFS1, the extra-pancreatic features associated
with Wolfram syndrome were present in only one child. This
is probably attributable to the early genetic diagnosis when
only diabetes is present and before the development of other
associated features, such as optic atrophy and deafness. The
child with a mutation in SLC29A3 had no clinical manifes-
tations attributed to H syndrome. The mutations in
SLC29A3 have also been detected in children with mild
manifestations and our findings in this child indicate that the
prevalence of H syndrome is likely to be underestimated as a
result of undiagnosed mild cases [28]. The child with a
mutation in SLC19A2 had developed other features of
thiamine-responsive megaloblastic anaemia syndrome, also
known as Roger’s syndrome, including anaemia, cardiac
defects and deafness; however, studies of other cases suggest
diabetes can be isolated and present before the appearance of
other features [38,39]. Prompt diagnosis is essential as more
than half of the individuals with follow-up data benefitted
from early treatment with thiamine, with some individuals
becoming insulin-independent [39].
We showed for the first time that ZnT8 antibodies could
be detected in 18.6% of Iranian children with a Type 1
diabetes phenotype who lack GAD and IA2 antibodies. This
is very similar to observations in European children with
Type 1 diabetes, where testing for ZnT8 antibodies increased
the number of individuals positive for only one autoantibody
by 14–18% [12,40]. This finding suggests that measuring
ZnT8 antibodies in addition to GAD and IA2 antibodies
could increase the sensitivity and specificity to detect the
presence of an immune-mediated disease process.
The present study has some limitations. First, we were
unable to assay serum C-peptide in our children to confirm
diagnosis of Type 1 diabetes; however, the present cohort
included children aged 9 months to 5 years and C-peptide
measurement is only discriminative 3 to 5 years after
diagnosis because of the ‘honeymoon period’ [41].
Second, antibody testing was performed at time of genetic
testing and not at the time of diagnosis. Previous studies have
shown that GAD, IA2 and ZnT8 antibody titres do not fall
significantly in the first 2 years after diagnosis [42,43] and
our cohort had a median diabetes duration of 1.6 years;
however, we acknowledge that antibodies may have been
present in the children with longer diabetes duration but may
have been no longer in circulation.
Third, for technical reasons of genotyping, we only used
nine common SNPs with the highest risk alleles for maxi-
mum discrimination between Type 1 diabetes and other
subtypes. However, it has been shown that other SNPs do
not substantially improve discriminatory ability as a result of
being rare or having a subtle effect size [15].
Fourth, our cohort included a small number of children
with monogenic diabetes (n = 6) and there will be a degree of
uncertainty in the estimates of sensitivity and specificity of
the genetic risk score to discriminate monogenic diabetes
from Type 1 diabetes. The utility of antibodies and genetic
risk score was determined in a cohort of children with age of
diagnosis of diabetes between 9 months and 5 years. In this
age group, Type 1 diabetes or rare recessive monogenic
forms will be the only subtypes, and Type 1 diabetes genetic
risk score and antibodies are always likely to be discrimina-
tive. This age range would exclude more common subtypes
of monogenic diabetes, as discussed above, and therefore
does not inform about MODY vs Type 1 diabetes.
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Further work is needed to validate the robustness of the
discriminative ability of the Type 1 diabetes genetic risk score
and antibodies in a larger cohort of people with diabetes
diagnosed up to the age of 30 or 35 years. This would enable
the genetic diagnosis of more common, dominant forms of
MODY and provide the power to test the ability of antibodies
and genetic risk score to distinguish Type 1 from bothMODY
and Type 2 diabetes in non-European populations.
The final limitation is that we used a genetic risk score that
was developed in British European individuals. It is possible
that population stratification, ethnicity and higher rates of
consanguinity may result in differences in the underlying risk
allele frequencies between European and Iranian populations.
No large-scale genome-wide SNP genotyping or sequencing
has been performed in the Iranian population and the true
frequency of the Type 1 diabetes risk alleles used in the genetic
risk score are not known. We also used odds ratios derived
from Europeans for the Type 1 diabetes genetic risk score. The
use of large genome-wide association studies to generate the
weights in the Type 1 diabetes genetic risk score means the
odds ratios are precise for a European population. It is
reassuring that the genetic risk score of Iranian people with
Type 1 diabetes did not differ significantly from Europeans.
European population-derived Type 1 diabetes risk alleles have
also been shown to discriminate Type 1 diabetes in Hispanic
andAfrican populations [44,45]. Furtherwork is needed to try
and define genetic relationships in a large Iranian cohort with
Type 1 diabetes to generate an Iranian-specific genetic risk
score; however, a critical issue is the power required to do this
and, without large sample sizes, it is possible that a genetic risk
score defined in a small cohort (e.g. <1000 cases) may not
improve discrimination of Type 1 diabetes.
In conclusion, we have demonstrated that the Type 1
diabetes genetic risk score has the potential to discriminate
Type 1 from monogenic diabetes in children diagnosed
between the ages of 9 months and 5 years from an Iranian
population with a large number of consanguineous unions.
Genetic risk score in combination with GAD, IA2 and ZnT8
autoantibody testing could be used to identify people with a
higher probability of having monogenic diabetes who could
then undergo genetic testing. Identification of these individ-
uals could potentially reduce the cost of treatment and
improve the management of their clinical course.
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